Compugen | CGEN - Cash And Equivalent


Compugen reported $10.28M in Cash and Equivalent for its fiscal quarter ending in June of 2026.





Cash And Equivalent Change Date
Arca Biopharma USD 191.52M 76.95M Sep/2026
aTyr Pharma USD 13.14M 3.02M Sep/2026
Bio Path 13.65M 3.37M Sep/2022
Brainstorm Cell Therapeutics USD 22K 7K Jun/2026
Cara Therapeutics USD 19.85M 883K Mar/2026
Clal Biotechnology ILS 5.73M 1.71M Dec/2023
Compugen USD 10.28M 2.15M Jun/2026
Immunic USD 186.63M 171.15M Mar/2026
Minerva Neurosciences USD 82.3M 70.02M Dec/2025
RedHill Biopharma USD 2.87M 1.75M Jun/2025
TherapeuticsMD 523K 89K Jun/2024